Conditions: Non-Small Cell Lung Cancer
Keywords: Advanced Stage IIIB/IV Non-Small Cell Lung Cancer
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 61
Healthy volunteers: no

Brief summary:
This is a clinical trial to determine the safety and tolerability of MK0683 in combination with gemcitabine and cisplatin and/or carboplatin.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: vorinostat intervention 2: Gemcitabine intervention 3: Platinum-based agent
Intervention descriptions: intervention 1: Dose escalation study: vorinostat 300-500 mg capsules once daily for 7-14 days in continuous cycles of 21 days intervention 2: Dose escalation study: Gemcitabine 1000-1250 mg/m2 will be given for 2 days in each 21 day cycle intervention 3: Cisplatin IV 75 mg/m2 will be given for 1 day in each 21 day cycle or carboplatin dosed according to renal function.

Protocol document: